Omeros Corporation

NASDAQ:OMER

Biotechnology

Healthcare
$14.55 +4.46%

+$0.43 today

Market cap
$1.08B
Beta
2.53
P/E (TTM)
8.4
EPS (TTM)
$1.20
52W Low $2.95High $17.65

Volume 2.53M

Average 1.55M

News

For Omeros Corporation, read summarized stories built from several publishers and recent headlines with links to the original coverage.

Earnings & Results

Omeros Beats Q3 Estimates as YARTEMLEA Sales Rise

Omeros reported third-quarter 2026 earnings of $0.06 per share, beating the consensus estimate of a loss of $0.05 per share and improving on a loss of $0.19 per share a year earlier. Sales of its transplant complication treatment YARTEMLEA rose year over year.

The company recorded a second consecutive quarter of positive operating cash flow, but a non-cash adjustment related to its convertible notes pushed it to a net loss for the period.

The quarter marks a swing from the company's recent full-year results: in fiscal 2025, Omeros reported a net loss of 3.4 million USD and diluted EPS of -0.05 USD.

More headlines

Recent coverage that has not been summarized. Links open the publisher's site.